← Leaderboards
Gregg N. Milligan
Children'S Hospital Med Ctr (Cincinnati)
$8,214,058
Attributed
$8,214,058
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,214,058 · 7
By mechanism
R01$5,687,862 · 3
R21$1,314,100 · 3
U01$1,212,096 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Med Ctr (Cincinnati)
Same institution · by research overlap
- Betsy C. Herold$27,491,366
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionVirusImmuneVaccinesT-LymphocyteResponseCellsVaginaAntigensPathogenSiteEpitheliumClinical TrialsImmunizationSimplexvirusImmune ResponseHerpes Simplex Virus VaccinesGenital HerpesGenital SystemMucous MembraneAmericanT Memory CellAnimalsImmunity
Grant awards (29)
Cervicovaginal Vaccine Delivery by Novel Pod Intravaginal Rings for Therapeutic Immunization Against HSV-2$196,470
R21 · FY2021 · AI · contact PI
Cervicovaginal Vaccine Delivery by Novel Pod Intravaginal Rings for Therapeutic Immunization Against HSV-2$249,440
R21 · FY2020 · AI · contact PI
Induction, maintenance, and function of genital tract-resident CD8+ T cells$387,500
R01 · FY2019 · AI · contact PI
Induction, maintenance, and function of genital tract-resident CD8+ T cells$387,500
R01 · FY2018 · AI · contact PI
Induction, maintenance, and function of genital tract-resident CD8+ T cells$387,500
R01 · FY2017 · AI · contact PI
Induction, maintenance, and function of genital tract-resident CD8+ T cells$387,500
R01 · FY2016 · AI · contact PI
Immunization with a Novel Single Cycle Flavivirus Particle Vector and Antigenic Peptide Nanofibers as a Prime-boost Vaccine Strategy against HSV-2$193,750
R21 · FY2016 · AI · contact PI
Immunization with a Novel Single Cycle Flavivirus Particle Vector and Antigenic Peptide Nanofibers as a Prime-boost Vaccine Strategy against HSV-2$232,500
R21 · FY2015 · AI · contact PI
Induction, maintenance, and function of genital tract-resident CD8+ T cells$193,750
R01 · FY2015 · AI · contact PI
Innate Immune Recognition Enhances Flavivirus Vaccine Efficacy$599,429
U01 · FY2010 · AI · contact PI
Protection of Genital Mucosa and Ganglia Against HSV-2$243,338
R01 · FY2010 · AI · contact PI
Innate Immune Recognition Enhances Flavivirus Vaccine Efficacy$612,667
U01 · FY2009 · AI · contact PI
Protection of Genital Mucosa and Ganglia Against HSV-2$245,796
R01 · FY2009 · AI · contact PI
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy$220,970
R21 · FY2009 · AI · contact PI
Protection of Genital Mucosa and Ganglia Against HSV-2$245,796
R01 · FY2008 · AI · contact PI
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy$220,970
R21 · FY2008 · AI · contact PI
Vaccine-elicited genital and neuronal T cell responses$353,197
R01 · FY2007 · AI · contact PI
Protection of Genital Mucosa and Ganglia Against HSV-2$250,557
R01 · FY2007 · AI · contact PI
Vaccine-elicited genital and neuronal T cell responses$363,746
R01 · FY2006 · AI · contact PI
Protection of Genital Mucosa and Ganglia Against HSV-2$258,040
R01 · FY2006 · AI · contact PI
Vaccine-elicited genital and neuronal T cell responses$372,500
R01 · FY2005 · AI
Protection of Genital Mucosa and Ganglia Against HSV-2$132,125
R01 · FY2005 · AI
Vaccine-elicited genital and neuronal T cell responses$372,500
R01 · FY2004 · AI
Vaccine-elicited genital and neuronal T cell responses$366,865
R01 · FY2003 · AI
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2$193,634
R01 · FY2003 · AI
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2$187,993
R01 · FY2002 · AI
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2$107,627
R01 · FY2001 · AI
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2$74,388
R01 · FY2001 · AI
PROTECTION OF GENITAL MUCOSA AND GANGLIA AGAINST HSV-2$176,010
R01 · FY2000 · AI